Fibroblast growth factor 23 and Klotho contribute to airway inflammation

What is it about?

Circulating levels of fibroblast growth factor (FGF) 23 are associated with systemic inflammation and increased mortality in chronic kidney disease. Here we show that FGF23 signaling is activated in COPD patients in plasma and lung and contributes to chronic airway inflammation. Therefore, development of future strategies to block FGF23 signaling in COPD might serve as a novel anti-inflammatory therapy for these patients.

Featured Image